



1FW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert A. Ashley Examiner: Unassigned
Serial No.: 10/757,656 Group Art Unit: 1617
Confirmation No: 3939 Docket: 512-53 DIV
Filed: January 14, 2004 Dated: May 24, 2006
For: METHODS OF TREATING
ACNE

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail;
postpaid in an envelope addressed to Commissioner for
Patents, PO Box 1450, Alexandria, VA 22313-1450

on May 24, 2006 Signature Carla H. Bryan

**SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R. §1.56, Applicant submits herewith the following Information Disclosure Statement in accordance with the provisions of 37 C.F.R. 1.97 and §1.98. The Information Disclosure Statement is being timely submitted under 37 C.F.R. 1.97(b)(4), i.e., before the mailing of a first office action.

UNITED STATES PATENT

<u>PATENTEE</u>	<u>PATENT NO.</u>	<u>ISSUE DATE</u>
Arbiser	6,673,843	January 6, 2004

UNITED STATES PATENT PUBLICATION

<u>APPLICANT</u>	<u>PUBLICATION NO.</u>	<u>PUBLICATION DATE</u>
Milstein	US 2003/0082120 A1	May 1, 2003

NON-PATENT PUBLICATIONS

1. Akamatsu et al. "Effects of subminimal inhibitory concentrations of minocycline on neutrophil chemotactic factor production in comedonal bacteria, neutrophil phagocytosis and oxygen metabolism." *Arch Dermatol Res* 283:524-528 (1991).
2. Bikowski et al. "Treatment of Rosacea with Doxycycline Monohydrate" *Cutis* 66:149-152 (Aug. 2000).
3. Golub et al. "Tetracyclines Inhibit Connective Tissue Breakdown: New therapeutic Implications for an Old Family of Drugs" *Critical Reviews in Oral Biology and Medicine*, 2(2):297-322 (1991).
4. Illig, L. (a) Original German article: "Positive Nebenwirkungen antibiotischer bzw. antimikrobieller Substanzen in der Therapie" (b) English translation: "Positive side effects of antibiotic and antimicrobial substances in therapy" *Infection*, 7 (Suppl. 6) 584-588 (1979).
5. Knight et al. "A follow-up of tetracycline-treated rosacea" *British Journal of Dermatology* 93:577-580 (1975).
6. Marks et al. "Comparative Effectiveness of Tetracycline and Ampicillin in Rosacea" *The Lancet* 1049-1052 (November 13, 1971).
7. Millar et al. "A general practice study investigating the effect of minocycline (Minocin) 50 mg bd for 12 weeks in the treatment of acne vulgaris" *The British Journal of Clinical Practice* 41(8):882-886 (August 1987).
8. Plewig et al. Acne: Morphogenesis and Treatment, Springer-Verlag 261, 297-301 (1975).


Applicant(s): Robert A. Ashley
Serial No: 11/757,656
Filed: January 14, 2004
Our Docket: 512-53 DIV
Page 3 of 3

9. Webster et al. "Suppression of Polymorphonuclear Leukocyte Chemotactic Factor Production in *Propionibacterium acnes* by Subminimal Inhibitory Concentrations of Tetracycline, Ampicillin, Minocycline, and Erythromycin" *Antimicrobial Agents and Chemotherapy* 21(5):770-772 (1982).

Copies of the references set forth above were provided in the parent application USSN 10/117,709, and a separate listing of the same has been set forth on the attached Form PTO-1449. The examiner is respectfully requested to consider each of these references in its entirety, and to indicate that she or he has done so by initialing the Form PTO 1449.

Applicant is not aware of any other references to be identified at this time. If the examiner has any questions or comments relating to the present application, she or he is respectfully invited to contact applicant's attorney at the telephone number set forth below.

Respectfully submitted,



Susan A. Sipos
Registration No.: 43,128
Attorney for Applicant

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
SAS/cb

221961_1



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 512-53 DIV	SERIAL NO. 10/757,656
	APPLICANT Robert A. Ashley	CONFIRMATION NO. 3939
	FILING DATE January 14, 2004	GROUP 1617

U.S. PATENT

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	6,673,843	1/6/04	Arbiser.	514	679	June 30, 1999

U.S. PATENT PUBLICATIONS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	20030082120	5/1/03	Milstein.	424	59	October 24, 2002

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1	Akamatsu, et al. "Effects of subminimal inhibitory concentrations of minocycline on neutrophil chemotactic factor production in comedonal bacteria, neutrophil phagocytosis and oxygen metabolism." <i>Arch Dermatol Res</i> 283:524-528 (1991)
	2	Bikowski, et al. "Treatment of rosacea with doxycycline monohydrate" <i>Cutis</i> , 66:149-152 (Aug 2000)
	3	Golub, et al. "Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs" <i>Critical Reviews in Oral Biology and Medicine</i> , 2(2):297-322 (1991)
	4	Illig "Positive side effects of antibiotic and antimicrobial substances in therapy" <i>Infection</i> 7 (Suppl. 6): S 584-588 (1979) (English translation. Original document in German.)
	5	Knight, et al. "A follow-up of tetracycline-treated rosacea" <i>British Journal of Dermatology</i> 93:577-580 (1975)
	6	Marks, et al. "Comparative effectiveness of tetracycline and ampicillin in rosacea" <i>The Lancet</i> , 1049-1052 (November 13, 1971)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 512-53 DIV	SERIAL NO. 10/757,656
	APPLICANT Robert A. Ashley	CONFIRMATION NO. 3939
	FILING DATE January 14, 2004	GROUP 1617

		7	Millar, et al. "A general practice study investigating the effect of minocycline (Minocin) 50 mg bd for 12 weeks in the treatment of acne vulgaris" <i>The British Journal of Clinical Practice</i> 41(8):882-886 (August 1987)
		8	Plewig, et al. <u>Acne: Morphogenesis and Treatment</u> , Springer-Verlag 297-301 (1975)
		9	Webster, et al. "Suppression of Polymorphonuclear Leukocyte Chemotactic Factor Production in <i>Propionibacterium acnes</i> by Subminimal Inhibitory Concentrations of Tetracycline, Ampicillin, Minocycline, and Erythromycin" <i>Antimicrobial Agents and Chemotherapy</i> 21(5):770-772 (1982)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.